Company news

Cel-Sci Corporation news in 2025

Cel-Sci Corporation's news releases, calls and decks from 2025, newest first.

View company

CEL-SCI Reports Fiscal 2025 Results

December 29, 2025

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

October 20, 2025

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

October 10, 2025

CEL-SCI Announces Closing of $10 Million Public Offering

August 29, 2025

CEL-SCI Announces Pricing of $10 Million Public Offering

August 27, 2025

CEL-SCI Announces Proposed Public Offering

August 27, 2025

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

August 14, 2025

CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

August 13, 2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

July 14, 2025

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

July 11, 2025

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

July 11, 2025

CEL-SCI Announces Closing of Public Offering

May 23, 2025

CEL-SCI Announces Pricing of Public Offering

May 21, 2025

CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

May 21, 2025

CEL-SCI Announces Combination of Common Stock

May 19, 2025

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

May 15, 2025

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

April 23, 2025

Decks in 2025